# Long-term interleukin-4 release from 3D printable affinity hydrogels promotes M2-like macrophage polarisation in vitro

**Authors:** George A. Loxley, Consuelo Coser, Amir M. Ghaemmaghami, Jing Yang

PMC · DOI: 10.1039/d4bm01623h · 2025-03-28

## TL;DR

Researchers developed a hydrogel that can slowly release Interleukin-4 for over two months, which helps guide immune cells in a lab setting.

## Contribution

The study introduces a 3D printable hydrogel system that enables long-term, sustained release of IL-4 with bioactive effects on macrophages.

## Key findings

- SPAK–PEGDA hydrogels achieved zero-order release of lysozyme for 70 days with tunable release rates.
- IL-4 released from 5% SPAK–10% PEGDA hydrogels maintained bioactivity, promoting M2-like macrophage polarization.
- 3D printed porous designs increased lysozyme release rates compared to non-porous designs of the same volume.

## Abstract

The biopharmaceutical industry for engineered protein drugs is rapidly increasing in size but there is a lack of controlled release vehicles to enable targeted delivery for regenerative medicine applications. In this study, we used photocrosslinkable 3-sulfopropyl acrylate potassium salt (SPAK)–poly(ethylene glycol) diacrylate (PEGDA) hydrogels to achieve controlled release of lysozyme for 70 days with zero-order release and tuneable release rate. Scaling down hydrogel volume and protein loading concentration to release Transforming growth factor beta-1 (TGF-β1) and Interleukin-4 (IL-4) resulted in low cumulative release, even without SPAK. Increasing PEGDA molecular weight from 4 kDa to 20 kDa improved TGF-β1 release but it still remained below 10% after 10 days. We observed sustained IL-4 release in the therapeutic ng mL−1 range for 73 days when loading IL-4 to 5% SPAK–10% PEGDA post photocrosslinking. Released IL-4 maintained bioactivity, promoting M2-like polarisation of THP-1 macrophages with day 53 supernatant, modelling long-term immunomodulation in vitro. We manufactured SPAK–PEGDA hydrogels by projection micro stereolithography, in which 3D printed 5% SPAK–10% PEGDA had an increased lysozyme release rate compared to its cast counterpart. 3D printed 5% SPAK–10% PEGDA with porous 3D design had an increased lysozyme release rate compared to a volume matched non-porous design. These findings highlight the potential of SPAK–PEGDA hydrogels for long-term cytokine delivery and show proof-of-concept for manipulating protein release kinetics with 3D printed hydrogel design.

Localised cytokine delivery is a promising strategy for modulating immune response and enhancing regenerative medicine therapies. SPAK-PEGDA hydrogels enable the long-term controlled release of lysozyme and the sustained release of Interleukin-4.

## Linked entities

- **Proteins:** lysozyme (lysozyme 1-like), IL4 (interleukin 4), GLI2 (GLI family zinc finger 2)
- **Chemicals:** 3-sulfopropyl acrylate potassium salt (PubChem CID 23663682), poly(ethylene glycol) diacrylate (PubChem CID 75282), PEGDA (PubChem CID 75282)

## Full-text entities

- **Genes:** IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, STK39 (serine/threonine kinase 39) [NCBI Gene 27347] {aka DCHT, SPAK}
- **Chemicals:** 3-sulfopropyl acrylate potassium salt (MESH:C000617094), PEGDA (MESH:C437167)
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11951857/full.md

---
Source: https://tomesphere.com/paper/PMC11951857